Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$41.21 USD

41.21
902,114

+0.03 (0.07%)

Updated Aug 14, 2024 12:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lilly (LLY) Inks Metabolic Disorders Therapy Development Deal

by Zacks Equity Research

Lilly (LLY) inks a strategic collaboration with Regor Therapeutics to discover and develop novel therapies for metabolic disorders.

Is GlaxoSmithKline (GSK) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how GlaxoSmithKline (GSK) and Omnicell (OMCL) have performed compared to their sector so far this year.

The Zacks Analyst Blog Highlights: Visa, United Parcel Service, TotalEnergies, GlaxoSmithKline and Micron

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Visa, United Parcel Service, TotalEnergies, GlaxoSmithKline and Micron

GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

GlaxoSmithKline (GSK) closed at $42.80 in the latest trading session, marking a +0.28% move from the prior day.

Mark Vickery headshot

Top Stock Reports for Visa, UPS & TotalEnergies

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), United Parcel Service, Inc. (UPS), and TotalEnergies SE (TTE).

AstraZeneca (AZN) Gets FDA Nod for COVID Prevention Drug

by Zacks Equity Research

With emergency approval from the FDA, AstraZeneca's (AZN) Evusheld is the first cocktail antibody drug approved in the United States to prevent COVID-19 symptoms before virus exposure.

Stock Market News for Dec 9, 2021

by Zacks Equity Research

U.S. stocks closed slightly higher on Wednesday, with major indexes hovering around their record highs, as reports suggested that the Omicron variant of the coronavirus looks less dangerous that it was earlier thought.

Best Income Stocks to Buy for December 9th

by Zacks Equity Research

GSK, BANR, RYN, and SBFG made it to the Zacks Rank #1 (Strong Buy) income stocks list on December 9, 2021.

Stock Market News for Dec 8, 2021

by Zacks Equity Research

U.S. stocks closed higher for the second consecutive session on Tuesday as investors shrugged off fears of the Omicron variant of the coronavirus after reports suggested that the mutant is less severe than originally thought.

Glaxo (GSK), Medicago COVID-19 Jab Effective Against Variants

by Zacks Equity Research

Glaxo (GSK) and Medicago's plant-based vaccine achieves more than 70% efficacy rate against COVID-19 and its major variants.

Anixa (ANIX) COVID Compounds Prove Effective Against Omicron

by Zacks Equity Research

Anixa Biosciences' (ANIX) potential COVID-19 compounds show effectiveness against the Omicron variant of COVID-19.

Sanofi's (SNY) Filing for Rare Disease Drug Accepted by EMA

by Zacks Equity Research

The EMA accepts Sanofi's (SNY) regulatory submission seeking approval for olipudase alfa, a potential treatment for acid sphingomyelinase deficiency.

Roche (RHHBY) Actemra Gets CHMP Recommendation for COVID-19

by Zacks Equity Research

The CHMP recommends EU approval for Roche's (RHHBY) Actemra to treat patients with severe COVID-19.

Merck (MRK) Pauses Enrolment in HIV-1 Prevention Studies

by Zacks Equity Research

Merck (MRK) pauses enrolment for two phase III studies evaluating islatravir for pre-exposure prophylaxis of HIV-1 infection, following the recommendation of an external data monitoring committee.

Bayer's (BAYRY) Phase III Study on Nubeqa Combo Meets Goal

by Zacks Equity Research

Bayer's (BAYRY) phase III study evaluating Nubeqa in combination with docetaxel and androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer meets the primary endpoint.

Merck's (MRK) Keytruda Gets FDA Nod for Expanded Melanoma Use

by Zacks Equity Research

Post FDA approval, Merck's (MRK) anti-PD-1 therapy Keytruda is now approved as an adjuvant treatment for adult & pediatric patients with stage IIB, IIC or III melanoma following complete resection.

Lilly (LLY) COVID-19 Antibody Gets FDA Nod for Use in Kids

by Zacks Equity Research

With the approval in children and infants, Lilly's (LLY) bamlanivimab with etesevimab can now be given as treatment and prevention options to high-risk individuals of any age.

Best Income Stocks to Buy for December 6th

by Zacks Equity Research

RC, GSK, BNS, and SPG made it to the Zacks Rank #1 (Strong Buy) income stocks list on December 6, 2021.

Novavax (NVAX) Starts Developing Omicron-Specific COVID Jab

by Zacks Equity Research

Novavax (NVAX) begins evaluating its COVID-19 vaccine against the Omicron variant. The company also starts developing an Omicron-specific COVID-19 vaccine.

GSK vs. NVO: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

GSK vs. NVO: Which Stock Is the Better Value Option?

Glaxo (GSK), Vir COVID Drug Appears Effective Against Omicron

by Zacks Equity Research

Glaxo (GSK) and Vir Biotechnology announce promising pre-clinical data from the study of their antibody candidate, sotrovimab, against mutations found in the Omicron variant.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Panel Vote for MRK COVID Pill, JNJ Omicron Jab Plan

by Kinjel Shah

FDA panel votes for Merck's (MRK) COVID-19 antiviral pill. AbbVie (ABBV) seeks approval for Skyrizi for Crohn's disease in Europe

Sage (SAGE), Biogen (BIIB) Report Data on Depression Drug

by Zacks Equity Research

Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a cohort of an ongoing phase III study, currently evaluating their investigational major depressive disorder drug zuranolone.

Merck (MRK) Vaxneuvance sBLA for Pediatrics Gets Priority Review

by Zacks Equity Research

Merck (MRK) is seeking label expansion for Vaxneuvance for use in pediatric patients aged six weeks through 17 years for the prevention of invasive pneumococcal disease. A decision is expected by on Apr 1, 2022.

AbbVie (ABBV) Files for Skyrizi to Treat Crohn's Disease in EU

by Zacks Equity Research

AbbVie (ABBV) submits a regulatory application in the European Union, seeking approval for risankizumab (Skyrizi) for the treatment of Crohn's disease.